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1612Objective: CRNN gene expression is downregulated in esophageal squamous cell carcinoma (ESCC), although
its clinical implications in esophageal cancer remain unclear.
Methods: We performed integrated microarray analysis and identified the CRNN gene as 1 of the major
downregulated genes in ESCC. CRNN downregulation was validated at the nucleic acid level in 16 ESCC cases
using complementary DNA microarray and at the protein level by immunohistochemical stains in an additional
220 ESCC cases. The clinicopathologic relevance and prognostic significance of CRNN expression in ESCC
were explored.
Results: Downregulated CRNN expression was noted at the messenger RNA and protein levels.
Immunohistochemical staining revealed negative and positive CRNN expression in 171 (77.7%) and
49 (22.3%) patients with ESCC, respectively. Patients with negative CRNN protein expression had an advanced
tumor invasion depth (P ¼ .002), advanced nodal involvement (P ¼ .014), and longer tumor length (P ¼ .037).
Patients with negative CRNN expression (median survival, 14.0 months; 5-year survival rate, 20.5%) had
poorer overall survival than those with positive expression (30.0 months and 40.3%, respectively; P ¼ .006).
On multivariate analysis, negative CRNN expression, nodal involvement, and distant metastasis remained
significant prognostic factors for poor overall survival (negative vs positive CRNN, hazard ratio, 1.464;
P ¼ .047).
Conclusions: Our analysis has highlighted the clinical implications of CRNN expression in ESCC. Loss of
CRNN expression correlated with advanced tumor length, greater tumor invasion depth, lymph node metastasis,
and poor survival in patients with ESCC. (J Thorac Cardiovasc Surg 2014;147:1612-8)Supplemental material is available online.Esophageal squamous cell carcinoma (ESCC) is an
aggressive malignancy with a dismal prognosis. Despite
advances in multimodal treatment, the 5-year overall
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The Journal of Thoracic and Cardiovascular Surwho have undergone curative surgical resection.1-4 We
have previously reported several clinicopathologic
parameters as significant prognostic factors (eg, tumor
invasion depth, tumor length, positive lymph node number,
and disease recurrence) for the identification of high-risk pa-
tients.3,4 Many genetic changes and biomarkers have been
reported to be involved in the development of esophageal
cancer. For example, activation of cyclooxygenase 2 and
overexpression of growth factors such as epidermal growth
factor, fibroblast growth factor, and C-erb B2 (Her2/neu)
can contribute to the progression from Barrett’s esophagus
to adenocarcinoma.5-7 Numerous genetic mutations, such
as p53, p21, p16, and cyclin D, have also been identified
in ESCC.7 With the advent of microarray and high-
throughput technology, genome-wide expression profiling
has contributed greatly to our understanding of the
fundamental cancer biology and the identification of new
biomarkers associated with tumor behavior and patient
outcomes.8-11 To explore the differentially expressed
(in particular, downregulated) genes in ESCC, we
analyzed 4 publicly available microarray data sets and
identified CRNN (official full name ‘‘cornulin’’) as 1 of the
major downregulated genes with a high normal/tumor
ratio. First cloned and reported in 2000, the CRNN gene
was identified as 1 of the downregulated genes ingery c May 2014
Abbreviation and Acronym
ESCC ¼ esophageal squamous cell carcinoma
Hsu et al General Thoracic Surgeryesophageal carcinoma.12 Subsequent high-throughput anal-
ysis of esophageal cancer also confirmed downregulation of
CRNN at the messenger RNA level.13,14 Pawar and
colleagues15 performed quantitative proteomic analysis
and identified CRNN as a fivefold downregulated protein
in ESCC tumor tissue versus adjacent normal epithelium.
A recent report also demonstrated downregulation of
CRNN protein expression in 239 of 266 (89%) ESCC
cases using immunohistochemical staining.16 However,
reports on the clinical implications of CRNN expression in
esophageal cancer have been limited. The relationship
between CRNN expression and ESCC tumor aggressiveness
and patient prognosis has not yet been reported. In the
present study, the downregulation of CRNN expression
was validated at the nucleic acid level using complementary
DNA microarray and at the protein level using
immunohistochemical staining in another 220 ESCC cases.
Furthermore, we explored the clinicopathologic relevance
and prognostic significance of CRNN expression in patients
with ESCC.G
T
SMETHODS
Experimental Design and Workflow
The present study was conducted in 3 consecutive phases: (1) an
integrated microarray analysis-based discovery screen; (2) an initial
validation of candidate biomarkers using complementary DNAmicroarray;
and (3) clinical validation of the protein biomarkers using immunohisto-
chemical staining in patients with ESCC who had undergone surgery and
had complete clinicopathologic and follow-up data available.
Microarray Data Set Collection and Analysis
Four independent data sets (GSE5364, GSE20347, GSE23400, and
GSE29001) were obtained from the National Center for Biotechnology
Information Gene Expression Omnibus database (available at: http://
www.ncbi.nlm.nih.gov/geo/).9-11 The GSE20347 and GSE29001 data
sets were obtained using Affymetrix HG U133A, version 2.0, chips, and
the other data sets were derived from Affymetrix HG U133A chips.
Quantile normalization was applied before analysis. Statistical analyses
of the microarray data were conducted using BRB-ArrayTools (Biometrics
Research Branch, Division of Cancer Treatment and Diagnosis, National
Cancer Institute, Bethesda, Md).17 A class comparison using paired t tests
with permutations was performed to identify differentially expressed genes
in squamous cell carcinoma and matched normal esophageal epithelium.
The threshold for significance was P< .001, determined from 10,000
random permutations.
Verification of Messenger RNA Expression by
Complementary DNA Microarray
To validate the results from the publicly available data sets, paired tumor
and adjacent normal tissues were collected from 16 patients with ESCC
who had undergone primary resection without neoadjuvant treatment.
The specimens were snap frozen in liquid nitrogen immediately after
resection and stored in liquid nitrogen until use. Total RNAwas extractedThe Journal of Thoracic and Carfrom the frozen tissues using the RNeasy RNA extraction kit
(Qiagen, Venlo, The Netherlands) plus DNase I treatment (Promega,
Madison, Wis) and then processed for microarray hybridization on
Affymetrix U133A GeneChips (Affymetrix Inc, Santa Clara, Calif)
according to the manufacturer’s instructions. The ‘‘.CEL’’ file format
expression data were read using BRB-ArrayTools (National Cancer
Institute, Bethesda, Md) with the guanine cytosine robust multi-array
analysis methods, using the ‘‘gcrma’’ package from Bioconductor, to
compute probe set summaries.
Verification of Protein Expression by
Immunohistochemical Staining
Immunohistochemical stains were performed in a surgical cohort of 220
patients undergoing resection for ESCC at Taipei Veterans General
Hospital from 1995 to 2000. Clinical data were obtained from the Cancer
Registry Database at our hospital. Overall survival, defined as the interval
from the date of diagnosis to the date of death or last known follow-up visit,
was used as a measure of prognosis. The pathologic data were also
collected and determined according to the American Joint Committee on
Cancer TNM classification, 7th edition.18
Immunohistochemical staining was conducted in the tissue microarray
format (Figure E1). After deparaffinization and rehydration, all sections
were heated in boiling buffer (10 mM sodium citrate, pH 6.0) for 10minutes
to retrieve antigenicity, immersed in 3% hydrogen peroxidase for 10minutes
to block endogenous peroxidase activity, and incubated at 4C overnight
with primary antibodies (anti-CRNN rabbit polyclonal antibody, 1:200,
11799-1-AP, Proteintech Group, Chicago, Ill). Visualization was achieved
by incubation with horseradish peroxidase-labeled secondary antibody
(goat anti-rabbit immunoglobulin) for 1 hour at room temperature, followed
by the addition of 3,30-diaminobenzidine as a chromogen to detect
antigen–antibody complexes (EnVisionþ System-HRP, Dako, Carpinteria,
Calif). The tissues were counterstained with hematoxylin and dehydrated.
The evaluation was performed by a pathologist who was unaware of the
patient’s characteristics. Normal esophageal mucosal cells served as a
positive control, because they are known to exhibit strongCRNN expression.
The sameprocedurewas followed, except the primary antibodywas replaced
with phosphate-buffered saline (Figure E2). Using adjacent normal mucosa,
which stained intensely, as an internal control, the staining intensity was
scored from 0 (no staining at all), 1 (weak), 2 (medium), to 3 (strong), and
staining extent was scored from 0 (0%), 1 (0%-5%), 2 (6%-50%), to 3
(51%-100%), according to the percentage of positive cells. The tumors
with strong intensity (intensity score 3) in6% of the tumor area (area score
2-3) were defined as exhibiting ‘‘positive’’ expression; otherwise, the tumor
was defined as having ‘‘negative’’ expression. The patients were defined as
CRNN expression-positive if 1 positive tissue core was noted.
Statistical Analysis
Pearson’s chi-square test was used to compare the categorical variables
and Student’s t test to compare the continuous variables. The survival
curves were plotted using the Kaplan-Meier method and compared using
the log-rank test. Multivariate analysis was performed using the Cox
regression model. All calculations for clinical relevance were performed
using Statistical Package for Social Sciences, version 17.0 (SPSS, Chicago,
Ill), software, and P<.05 was considered significant.
Ethical Statement
The institutional review board of Taipei-Veterans General Hospital
approved this study and granted a waiver of the informed consent process.
RESULTS
Analysis of Publicly Available Microarray Data Sets
A total of 95 cases from 4 independent data sets were
included in our analysis (data sets GSE5364, GSE20347,diovascular Surgery c Volume 147, Number 5 1613
FIGURE 1. Representative images of immunohistochemical stains in
esophageal squamous cell carcinoma sections: A, no staining at all, defined
as negative CRNN staining; B, little staining, defined as negative CRNN
staining; and C, positive CRNN staining.
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SGS23400, and GSE29001 included 13, 17, 53, and 12 cases,
respectively.). Using P<.001 as the threshold, 796, 1728,
3315, and 1443 genes were found to be upregulated in
ESCC in the GSE 5364, GSE20347, GSE23400, and
GSE29001 data sets, respectively. In addition, 712, 1797,
4147, and 1518 genes were downregulated in the
corresponding tumor tissues. To identify a target for
additional analysis, we first selected the top 50 genes with
the greatest normal/tumor ratio (ie, the genes most strongly
downregulated in the ESCC tumors) in each data set.
Eighteen genes overlapped in all 4 data sets (Table E1).
Although the ‘‘CRISP3’’ gene ranked first in all 4 data
sets, it is a secretory protein, whose cellular component is
‘‘extracellular matrix’’ according to the Gene Ontology
project. Therefore, we selected ‘‘CRNN,’’ which ranked
second in 3 of the 4 data sets and third in the fourth, for
additional study.
Verification of Messenger RNA Expression by
Complementary DNA Microarray in a Validation
Cohort
The mean age of the 16 patients with ESCC in the
validation cohort was 62.6  13.8 years; 15 were men. The
cancer was stage T1-T2 and T3-T4 in 4 and 12 patients,
respectively. Of the 16 patients, 10 presented with positive
lymph node involvement; none had distant metastasis. In
the analysis of the differentially expressed genes, 1989
target genes (1005 upregulated and 984 downregulated)
were differentially expressed in the tumor and normal
tissue samples using a threshold of P < .001 under
10,000 permutations. Regarding CRNN (220090_at) gene
expression, the first quartile, median, and third quartile of
log-transformed signal in the normal mucosa and tumor
tissue was 13.07, 13.31, and 13.51 and 2.24, 2.28, and 3.18,
respectively (Figure E3). CRNN expression in the tumor
tissue was significantly lower than that in the normal mucosa
(384.2-fold in normal vs tumor tissue, P ¼ 4 3 107).
Thus, the downregulation of CRNN transcripts in ESCC
was validated in our own microarray data set.
Clinical Correlation of CRNN Protein Expression
The immunohistochemical staining results were similar
to those of the gene expression profiles. Although the
normal mucosa had uniformly intense CRNN expression,
negative and positive CRNN expression was noted in 171
(77.7%) and 49 (22.3%) ESCC tumors, respectively.
Representative views of the immunohistochemical stains
are shown in Figure 1. The relationship between the clinical
characteristics and immunohistochemical staining results
are listed in Table 1. CRNN expression correlated
significantly with the tumor invasion depth. Negative
CRNN expression was noted in 9 of 20 (45.0%), 44 of 57
(77.2%), 98 of 120 (81.7%), and 20 of 23 (87.0%) patients
with stage T1, T2, T3, and T4 disease, respectively.1614 The Journal of Thoracic and Cardiovascular SurIn contrast, 53 of 171 (31.0%) and 118 of 171 (69.0%)
patients with negative CRNN expression had stage T1-T2
and T3-T4 tumors, respectively. A greater proportion of
patients with positiveCRNN expression had stage T1-T2 tu-
mors (T1-T2, 49.0% [24 of 49]; T3-T4, 51.0% [25 of 49];gery c May 2014
TABLE 1. Relationship between clinicopathologic features and
immunohistochemical staining results
Variable
CRNN expression
P valueNegative Positive
Patients (n) 171 (77.7) 49 (22.3)
Age (y) 65.3  10.6 64.1  9.6 .491
Gender .631
Male 161 (94.2) 47 (95.9)
Female 10 (5.8) 2 (4.1)
Depth of invasion (T stage) .002*
T1 9 (5.3) 11 (22.4)
T2 44 (25.7) 13 (26.5)
T3 98 (57.3) 22 (44.9)
T4 20 (11.7) 3 (6.1)
Nodal status (N stage) .014*
N0 65 (38.0) 31 (63.3)
N1 50 (29.2) 10 (20.4)
N2 37 (21.6) 4 (8.2)
N3 19 (11.1) 4 (8.2)
Distant metastasis (M stage) .606
M0 165 (96.5) 48 (98.0)
M1 6 (3.5) 1 (2.0)
Stage .002*
I 11 (6.4) 10 (20.4)
II 58 (33.9) 23 (46.9)
III 96 (56.1) 15 (30.6)
IV 6 (3.5) 1 (2.0)
Differentiationy .141
Well 8 (7.8) 2 (5.9)
Moderate 74 (72.5) 30 (88.2)
Poor 20 (19.6) 2 (5.9)
Locationz .865
Upper third 18 (11.7) 6 (14.3)
Middle third 91 (59.1) 25 (59.5)
Lower third 45 (29.2) 11 (26.2)
Tumor length (cm)z 5.3  2.3 4.5  2.4 .037*
Data presented as mean  standard deviation or n (%). *P< .05 was considered
significant. yData available for 136 patients. zData available for 196 patients.
TABLE 2. Relationship between clinicopathologic features and
overall survival
Variable
Patients
(n)
5-y Survival
rate (%)
Median
survival (mo)
P
value
Age (y) .080
66 109 27.5 19.0 (13.5-24.5)
>66 111 22.1 14.0 (9.4-18.6)
Gender .870
Male 208 24.8 16.0 (12.7-19.3)
Female 12 25.0 22.0 (5.1-39.0)
Depth of invasion
(T stage)
.005*
T1 20 43.3 45.0 (0.0-101.8)
T2 57 29.6 24.0 (12.3-35.7)
T3 120 21.6 15.0 (11.3-18.7)
T4 23 13.0 9.0 (5.9-12.1)
Nodal status
(N stage)
<.001*
N0 96 38.8 29.1 (18.0-40.1)
N1 60 26.1 14.2 (10.6-17.8)
N2-N3 64 3.1 11.0 (8.4-13.6)
Distant metastasis
(M stage)
<.001*
M0 213 25.6 18.0 (14.1-21.9)
M1 7 0.9 7.0 (3.2-10.8)
Stage <.001*
I 21 51.1 68.0 (0.0-154.9)
II 81 37.8 29.0 (17.3-40.7)
III 111 12.0 13.0 (10.1-15.9)
IV 7 0.0 7.0 (3.2-10.8)
Differentiationy .465
Well 10 20.0 13.0 (0.0-30.0)
Moderately 104 24.0 17.0 (11.7-22.3)
Poorly 22 31.8 9.0 (0.0-19.1)
Locationz .700
Upper third 24 18.8 13.0 (4.6-21.4)
Middle third 116 22.0 15.0 (10.2-19.8)
Lower third 56 23.2 16.0 (10.5-21.5)
Tumor length (cm) .157
<5 88 25.7 17.0 (6.0-28.0)
5 109 18.8 14.0 (10.5-17.5)
CRNN expression .006*
Negative 171 20.5 14.0 (11.1-16.9)
Positive 49 40.3 30.0 (24.6-35.4)
Data in parentheses are 95% confidence intervals. *P<.05 was considered significant
by log-rank test. yData available for 136 patients. zData available for 196 patients.
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SP ¼ .002). CRNN expression also correlated significantly
with lymph node involvement. Negative CRNN expression
was noted in 65 of 96 (67.7%) and 106 of 124 (85.5%)
patients with node-negative and node-positive disease. In
contrast, 65 of 171 (38.0%) and 56 of 171 (32.7%) patients
with negative CRNN expression had stage N0 and tumors
with advanced lymph node involvement (stage N2-N3),
respectively. A greater proportion of patients with positive
CRNN expression had N0 tumors (N0, 31 of 49 [63.3%];
N2-N3, 8 of 49 [16.4%]; P ¼ .014). In addition, CRNN
expression correlated with tumor stage and tumor length.
The patients with negative CRNN expression were more
frequently diagnosed with stage III-IV than were those
with positive CRNN expression (59.6% vs 32.6%,
P ¼ .002). Patients with negative CRNN expression also
had longer tumor length than those with positive CRNN
expression (5.3  2.3 cm vs 4.5  2.4 cm, P ¼ .037).The Journal of Thoracic and CarSurvival Effect of CRNN Protein Expression
In the survival analysis, the mean follow-up duration for
all patients was 35.1  41.0 months (median, 16.0; range,
0.0-161.0). The median survival and 5-year overall survival
rate in the entire cohort was 17.0 months (95% confidence
interval, 13.2-20.8) and 24.8%, respectively. In addition to
the T, N, and M stage, CRNN expression was also a
significant prognostic factor (Table 2). Patients with
positive CRNN expression had a median survival of
30.0 months (95% confidence interval, 24.6-35.4) and adiovascular Surgery c Volume 147, Number 5 1615
FIGURE 2. Patients with positive CRNN protein expression (red line) had
significantly better overall survival than those with negative CRNN
expression (blue line).
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negative CRNN expression had a median survival of
14.0 months (95% confidence interval, 11.1-16.9) and a
5-year survival rate of 20.5%. The survival plot indicated
that patients with positive CRNN expression had better
survival than those with negative CRNN expression
(P ¼ .006; Figure 2). Survival analyses stratified by the
T, N, and pathologic stage also showed a trend toward
better survival for patients with positive CRNN
expression than for those with negative CRNN expression,
although the trend was not significant (Figure E4). On
multivariate analysis, negative CRNN expression,
along with nodal involvement and distant metastasis,
remained an independent predictor for poor overall survival
(CRNN, positive vs negative, hazard ratio, 0.683; P ¼ .047;
Table 3).TABLE 3. Multivariate analysis for overall survival
Variable HR 95% CI P value
Depth of invasion .140
T1/2 1 —
T3/4 1.285 0.921-1.795
Nodal status .001*
Negative 1 —
Positive 1.773 1.284-2.448
Distant metastasis .004*
M0 1 —
M1 3.231 1.469-7.106
CRNN expression .047*
Negative 1 —
Positive 0.683 0.469-0.995
HR, Hazard ratio; CI, confidence interval. *P<.05 was considered significant by Cox
regression model.
1616 The Journal of Thoracic and Cardiovascular SurDISCUSSION
Microarray technology is commonly used in genome-
wide expression analysis and provides novel insight into
many complex human diseases. In the present study, we first
selected the top 50 genes from each data set with the
greatest normal/tumor ratio; 18 of these genes overlapped
among the databases. To correlate gene expression with
gene function, a Gene Ontology analysis was performed
using the web-based toolkit, DAVID Bioinformatics
Resources (National Institute of Allergy and Infectious
Disease, National Institutes of Health, Bethesda, Md).19
The Gene Ontology enrichment analyses of these 18 genes
indicated significant perturbation in the ‘‘epithelial cell
differentiation’’-related annotations (P ¼ 1.8e7). In
addition to the corresponding genes, which included FLG,
KRT14, SCEL, SPINK5, TGM1, and TGM3, the target
gene ‘‘CRNN’’ played a role in epidermal differentiation,
indicating that a loss of gene expression in ‘‘epithelial
cell differentiation’’ is a major process during ESCC
development.
The CRNN gene is a member of the ‘‘fused gene family,’’
a group of genes present in the epidermal differentiation
complex, a 2.5-Mbp region on chromosome 1q21 contain-
ing a high density of structurally and functionally related
genes involved in terminal epidermal differentiation. The
encoded product is a protein of 495 amino acids containing
2 EF-hand Ca2þ-binding domains in its N-terminus and 2
glutamine- and threonine-rich 60 amino acid repeats in its
C-terminus.12 Because of its expression in the upper layer
of the squamous epithelium, it has been termed ‘‘cornulin’’
and has been suggested to have an important role in
epidermal differentiation.20 CRNN has also been referred
to as squamous epithelial heat shock protein-53 and
functions as a stress-responsive factor.21 Molecular studies
of squamous epithelial heat shock protein-53 have shown
that its expression helps maintain the barrier function in
the squamous epithelium in response to injury and functions
as a survival factor in mammalian cell lines. Darragh and
colleagues22 observed that squamous epithelial heat shock
protein-53 attenuates deoxycholic acid-mediated elevations
in intracellular free calcium and deoxycholic acid-induced
apoptotic cell death. They suggested it might function
between the signal cascade initiated by exposure and the
trigger that releases calcium, leading to apoptosis.22
Regarding the expression of CRNN in cancer tissue, its
expression was high in the adjacent normal esophageal
mucosa but was dramatically reduced or absent in the
esophageal cancer cell lines and primary esophageal tumor
tissue samples.12-16 In addition to esophageal cancer,CRNN
expression is also downregulated in head and neck
squamous cell carcinoma, tongue cancer, and cervical
cancer.23-26 Imai and colleagues27 reported that CRNN
overexpression in oral cancer cells causes a significantgery c May 2014
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sion at the G1/S phase, with downregulation of cyclin D1
expression. Their results suggested that CRNN plays a
role in controlling cell cycle progression and that CRNN
downregulation might be linked to tumor progression.27
The results of these studies have suggested that the loss of
CRNN expression might result in an abnormal response of
the esophageal epithelium to environmental stimulation,
possibly leading to cancer formation owing to deregulated
cell cycle control. However, the mechanism of CRNN
downregulation remains unknown. In the Catalogue of
Somatic Mutations in Cancer database (available at:
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/),
CRNN mutation was noted in only 1 of 12 ESCC samples
(8.3%), which could not explain the frequency of weak
protein expression in immunohistochemical staining.
The clinical relevance of CRNN expression, especially in
esophageal cancer, remains largely unknown. Only limited
reports could be found in the published data. Pawar and
colleagues16 demonstrated downregulation of CRNN
expression in 89% of ESCC cases, a greater rate than
observed in our study (77.7%). This discrepancy might
have resulted from differences in the antibodies used
(HPA024343 from Human Protein Atlas vs 11799-1-AP
from Proteintech) and the method of immunohistochemical
scoring. Although staining was scored according to both the
intensity and the area in our study, only the staining inten-
sity was assessed in the study by Pawar and colleagues.16
In our study, tumors with strong intensity in 6% of the
tumor area were defined as ‘‘positive’’ and patients were
grouped as having positive CRNN expression if any tissue
core showed ‘‘positive expression.’’ Few reports have
focused on the clinical relevance of CRNN gene expression.
Zhang and colleagues28 reported the association between
polymorphisms of CRNN and the susceptibility to esopha-
geal cancer. They found that subjects with the 1139CC
genotype had a greater risk of developing ESCC than those
with the 1139GG genotype.28 In the expression profiling
study by Luthra and colleagues,29 the patients with high
epidermal differentiation complex (IVL, CRNN, NICE-1,
S100A2, and SPPR3) gene expression were more likely to
achieve a pathologic complete response to neoadjuvant
chemoradiotherapy, suggesting that the expression of the
epidermal differentiation complex gene cluster, including
CRNN, might be a predictor of chemoradiotherapy
response.29
In the present study, we have demonstrated the
correlation between a loss of CRNN expression and longer
tumor length, deeper tumor invasion depth, more advanced
lymph node metastasis, and poorer survival. Our analysis
has highlighted the clinical role of CRNN expression in
ESCC. However, we do not know the mechanism of
CRNN downregulation. Although CRNN expression can
be a prognosticator and predictor for the treatmentThe Journal of Thoracic and Carresponse,16 no evidence is available to suggest that
CRNN might be a therapeutic target. Additional
investigation of the underlying mechanism of CRNN
downregulation is critical to defining how CRNN
contributes to ESCC carcinogenesis, and the clinical
implications of CRNN expression should be validated in a
larger clinical cohort.References
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FIGURE E1. Tissue microarray sections.
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FIGURE E2. Left, Positive and, right, negative controls. Normal esophageal mucosal cells served as a positive control, because they are known to exhibit
strong CRNN expression. The same procedure was followed, except that the primary antibody was replaced with phosphate-buffered saline.
FIGURE E3. CRNN expression in 16 patients with esophageal squamous
cell carcinoma patient cohort. The CRNN expression in the tumor tissue
was significantly lower than that in the normal mucosa (P ¼ 4 3 107).
General Thoracic Surgery Hsu et al
1618.e2 The Journal of Thoracic and Cardiovascular Surgery c May 2014
G
T
S
FIGURE E4. Survival analyses stratified according to A and B, T stage, C and D, N stage, and E and F, pathologic stage also showed a trend toward better
survival in patients with positive CRNN (green lines) expression compared with those with negative CRNN expression (blue lines), although the trend was
not significant.
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TABLE E1. CRNN normal/tumor ratio and rank in each data set
Gene symbol Description
Normal tissue/tumor ratio (rank)
GSE5364 GSE20347 GSE23400 GSE29001
CEACAM5 CEA-related cell adhesion molecule 5 10.71 (48) 16.04 (27) 4.20 (49) 64.46 (23)
CEACAM6 CEA-related cell adhesion molecule 6
(nonspecific cross-reacting antigen)
11.13 (42) 15.41 (28) 5.14 (26) 44.82 (32)
CLCA4 Chloride channel accessory 4 46.14 (3) 40.46 (7) 11.35 (5) 101.24 (11)
CRCT1 Cysteine-rich C-terminal 1 28.8 (10) 49.53 (4) 9.59 (7) 157.82 (7)
CRISP3 Cysteine-rich secretory protein 3 94.32 (1) 145.08 (1) 20.34 (1) 1260.46 (1)
CRNN Cornulin 61.57 (2) 84.39 (2) 13.13 (3) 345.2 (2)
ENDOU 26 Serine protease 20.79 (21) 23.85 (13) 7.18 (12) 162.87 (6)
FLG Filaggrin 23.21 (15) 19.01 (19) 5.63 (20) 121.2 (9)
HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 12.61 (18) 20.91 (16) 6.00 (17) 95.05 (13)
KLK13 Kallikrein-related peptidase 13 8.77 20.21 7.4 35.78
KRT4 Keratin 4 26.62 (11) 33.98 (9) 6.19 (18) 70.18 (22)
MAL Mal, T-cell differentiation protein 28.89 (9) 57.86 (3) 16.35 (2) 50.64 (29)
SCEL Sciellin 34.38 (5) 41.05 (6) 12.18 (4) 88.73 (15)
SLURP1 Secreted LY6/PLAUR domain containing 1 30.31 (8) 32.55 (10) 8.14 (9) 73.7 (20)
SPINK5 Serine peptidase inhibitor, Kazal type 5 22.86 (16) 32.39 (11) 7.08 (14) 35.98 (40)
TGM1 Transglutaminase 1 (K polypeptide epidermal type I,
protein-glutamine-gamma-glutamyltransferase)
23.4 (13) 10.97 (45) 4.51 (36) 42.77 (35)
TGM3 Transglutaminase 3 (E polypeptide,
protein-glutamine-gamma-glutamyltransferase)
32.71 (7) 47.42 (5) 10.65 (6) 105.77 (10)
TMPRSS11E Transmembrane protease, serine 11E 33.02 (6) 24.15 (12) 9.05 (8) 81.78 (17)
CEA, Carcinoembryonic antigen.
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